Antioxidant composition

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents an antioxidant composition containing lithium aspartate in amount of 40-60 wt% and lithium succinate in amount of 40-60 wt%. Disclosed composition allows for long-term storage and retains activity at room temperature for six months.

EFFECT: invention provides a wider range of antioxidant agents.

1 cl, 1 tbl, 3 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.

EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.

4 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.

EFFECT: novel compound, possessing useful biological properties, has been obtained.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.

EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.

4 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.

EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compositions and methods of delivering water-soluble and lipid-soluble nutrients. A liquid nutritional composition contains an emulsion which contains docosahexaenoic acid, where the emulsion is dispersed in an aqueous component containing at least one of amino acid components selected from a group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and a protein surfactant containing at least about 90 wt % α-lactalbumin. The α-lactalbumin is present in an amount between about 0.1% and about 1.0% of the nutritional composition. Disclosed is a method for supplemental feeding of a subject, which includes administering said liquid nutritional composition to the subject. The subject can be a premature infant.

EFFECT: invention enables to prevent or correct nutritional deficiency in subjects in need of low-volume supplemental feeding, such as premature infants.

20 cl, 1 dwg, 3 tbl

FIELD: nanotechnology.

SUBSTANCE: shell of the nanocapsules is used as apple or citrus high- or low-esterified pectin, and the core - as L-arginine. According to the inventive method, L-arginine is suspended in benzene, the resulting mixture is dispersed into a suspension of apple or citrus high- or low-esterified pectin in benzene in the presence of the preparation E472s while stirring 1000 revolutions per second. Then carbon tetrachloride is added, the resulting suspension of the nanocapsules is filtered and dried at room temperature. The process is carried out for 15 minutes.

EFFECT: simplification and acceleration of the process of producing the nanocapsules, and increase in the yield by weight.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiovascular surgery and cardiology, and deals with complex correction of immunoinflammatory responses of cardiovascular bed. For this purpose, in case of presence of high level of circulating immune complexes and/or complement in patient, three sessions of plasmapheresis in accordance with conventional methods, and in case of low level of IgG and reduced phagocytic activity of neutrophils and monocytes, as well as in case of confirmed autoimmune process, a course of intravenous infusions of human polyvalent immunoglobulin is carried out in accordance with conventional schemes.

EFFECT: method provides reduction of both hypo- and hyperactive disorders in immune system of patients and resulting increase of efficiency of treatment of cardiovascular system diseases.

3 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining L-arginine nanocapsules in sodium alginate envelope. In the process of method realisation L-arginine is suspended in benzene. Obtained mixture is dispersed into suspension of sodium alginate in hexane in presence of preparation E472c with mixing at 1000 rev/sec. After that, chloroform is added, and obtained suspension of nanocapsules is filtered and dried at room temperature. Process is realised for 15 minutes.

EFFECT: method in accordance with invention provides simplification and acceleration of process of obtaining nanocapsules and increased output by weight.

3 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.

EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.

10 cl, 4 ex, 3 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with stable composition for provision of subject with therapeutically or prophylactically effective amount of alpha-1 protease inhibitor (API), containing alpha-1 protease inhibitor (API) and at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, where said composition includes one or more auxiliary substances, where at least one amino acid is present in composition in the total amount of amino acid from approximately 0.01 M to approximately 3 M. Group of inventions also deals with set for treatment or prevention of API-associated disease or condition, which includes said composition; application of at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, for stabilisation of composition, containing alpha-1 protease inhibitor (API).

EFFECT: group of inventions provides stability of API composition.

15 cl, 27 dwg, 5 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects.

EFFECT: obtained samples are characterised by a uniform porous structure with the simultaneous reduction of calcium phosphate dimensions to a nano-level with the reduction of the number of material obtaining operations.

2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6.

EFFECT: effective management of the clinical course of the retinal venous thrombosis by considerable reduction of postoperative haemophthalmias.

2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relate to field of pharmaceutics, in particular, to pharmaceutical composition for treatment of phenylketonuria, which contains effective quantity of version of Anabaena variabilis (AvPAL) phenylalanine-ammonia-lyase, where claimed version additionally contains polyethylenglycol, as well as pharmaceutically acceptable carrier, which contains stabiliser, where stabiliser represents L-phenylalanine, trans-cinnamic acid or benzoic acid. Also claimed are: method of phenylketonuria treatment and method of reducing phenylalanine concentration in subject's blood.

EFFECT: group of inventions ensure application of prokaryotic PAL, which has higher phenylalanine-converting activity and/or lower immunogenicity in comparison with PAL of wild type.

56 cl, 19 ex, 11 tbl, 19 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.

EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.

11 cl, 15 dwg, 5 tbl